BnH-015B Clinical Trial in Moderate Alzheimer's Disease

Summary

BnH-015B is a small molecule compound that targets the GluN2B binding site on NMDA receptors and positively modulates. BnH-015B has shown, through nonclinical trials, to improve symptoms of cognitive decline by regulating the BDNF/TRKβ and microglia-mediated IL-33/OPN signaling pathways; therefore, it is expected to be a promising new drug that can significantly improve symptoms associated with Alzheimer's disease, including memory loss.

Conditions

• Alzheimer Disease

Interventions

DRUG

BnH-015B 5 mg

Korean / 3 on BnH-015B, 1 on placebo

DRUG

BnH-015B 10 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 20 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (Dietary impact)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg

Caucasian / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 80 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 160 mg

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (MAD)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 80 mg (MAD)

Korean / 6 on BnH-015B, 2 on placebo

DRUG

BnH-015B 40 mg (Part II)

Korean / 9 subjects

DRUG

BnH-015B 80 mg (Part II)

Korean / 9 subjects

DRUG

BnH-015B Placebo (Part II)

Korean / 6 subjects

Sponsors & Collaborators

• BnH Research

  lead INDUSTRY

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

45 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-10-22

Primary Completion

2026-04-30

Completion

2026-06-30

Countries

• South Korea

Study Locations